TITLE

USING THE WRITTEN DESCRIPTION REQUIREMENT TO LIMIT BROAD PATENT SCOPE, ALLOW COMPETITION, AND ENCOURAGE INNOVATION IN BIOTECHNOLOGY

AUTHOR(S)
Mull, William C.
PUB. DATE
June 2004
SOURCE
Health Matrix: Journal of Law-Medicine;Summer2004, Vol. 14 Issue 2, p393
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the U.S. Court of Appeals for the Federal Circuit's use of the written description requirement of the Patent Act to limit the scope of biotechnology patents. Significance of patent protection to the biotechnology industry; Overview of biotechnology and the basics of patent law; Application of the written description requirement in biotechnology patents; Importance of limiting the scope of patent protection in promoting the advancement of biotechnology.
ACCESSION #
14497485

 

Related Articles

  • Biotechnology's Uncertainty principle. Burk, Dan L.; Lemley, Mark A. // Case Western Reserve Law Review;Spring2004, Vol. 54 Issue 3, p691 

    Discusses the uncertainty of the patent standards covering the products of the biotechnology industries in the U.S. Formulation of legal rules in the patent law to govern the validity and infringement of patents in a wide variety of technologies; Failure of the statute to distinguish between...

  • Changes to Patent System May Harm Biotechs. Weeks, Katie // San Diego Business Journal;5/8/2006, Vol. 27 Issue 19, p17 

    The article reports on the changes made for the patent systems in the biotechnology company proposed by the U.S. House of Representatives and the U.S. Patent and Trademark Office. One of the proposed changes is to choose a system that grants patents based on the first person to file instead of...

  • Intellectual Property Protection in China: Does it Warrant Worry? Langer, Eric // BioPharm International;May2007, Vol. 20 Issue 5, p20 

    The article discusses issues concerning the intellectual property protection in China. Some biopharmaceutical companies has worried that the intellectual property in China is unprotectable wherein the companies discarded its plan to operate business in the country. However, most foreign...

  • Patent reform acts ugly.  // Nature Biotechnology;Nov2007, Vol. 25 Issue 11, p1187 

    The article relates the author's view on the controversy behind the U.S. patent system reform and how it affects the biotechnology industries. The author shares that the Patent Reform Act of 2007 seems to stop the biotechnology revolution in the U.S. He believes that there are many deals to...

  • How a large biotechnology company teamed with a translation service provider to define best practices. Coombs, Jeremy // Journal of Commercial Biotechnology;Jan2014, Vol. 20 Issue 1, p49 

    According to the World Intellectual Property Organization, nearly 100,000 pharmaceutical and biotechnology patent applications are filed each year around the world, and the trend is increasing. These companies have very little room for error in the work they conduct each day. As a result, the...

  • Study:Patent Reform May Harm Biotech,Add Costs.  // Bioworld Week;2/18/2008, Vol. 16 Issue 7, p4 

    The article reports on the result of the study conducted by the Biotechnology Industry Organization (BIO) which focuses on the impact of the proposed patent reform legislation towards the biotechnology industry in the U.S. BIO stresses that provisions on the legislation which includes the...

  • Patently transparent.  // Nature Biotechnology;May2006, Vol. 24 Issue 5, p474 

    The article focuses on the challenges facing the Patent and Trademark Office regarding the proliferation of gene patents and the increasing profusion of biotechnology patents and licenses with overlapping and competing rights in the U.S. To address the situation, biotechnology industry experts...

  • The patentability of human embryonic stem cells in Europe. Porter, Gerard; Denning, Chris; Plomer, Aurora; Sinden, John; Torremans, Paul // Nature Biotechnology;Jun2006, Vol. 24 Issue 6, p653 

    The article examines the impact of the directive by the European Patent Office on human embryonic stem (hES) cells patenting strategy and its implications on biotechnology industries in Europe. The rule 23 section c of the European Patent Convention directive had prohibited patent protection for...

  • Patenting biotechnology inventions in China. Lui, Jacqueline // Nature Biotechnology;Jan2001, Vol. 19 Issue 1, p83 

    Provides an overview of the main requirements for obtaining a patent in China, focusing on the aspects unique to biotechnology. List of subject matter excluded from patent protection under article 25 of the Chinese Patent Law; Patentable subject matter; Types of acceptable claim language and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics